Aspirin for evidence-based preeclampsia prevention trial: effects of aspirin on maternal serum pregnancy-associated plasma protein A and placental growth factor trajectories in pregnancy

CondensationShort title: Aspirin and serum pre-eclampsia biomarkers Tweetable Statement: Among participants of the ASPRE trial who were at increased risk of preterm pre-eclampsia, aspirin did not modify the trajectories of first trimester serum preeclampsia biomarkers during pregnancy. AJOG at a Glance A.Why was this study conducted?Aspirin effectively prevents preterm pre-eclampsia.However, its precise mechanism of action and effects on serum biomarkers remain unclear. B. What are the key findings?In participants of the ASPRE trial at high risk of preterm pre-eclampsia identified in the first trimester, daily aspirin 150 mg from the first trimester to 36 weeks did not modify trajectories of serum PAPP-A or PlGF on serial measurements throughout pregnancy. C. What does this study add to what is already known?Although smaller studies have suggested that aspirin use may increase serum PAPP-A and PlGF, we have found no evidence that aspirin affects these biomarkers' trajectories in pregnancy.It is unlikely that PAPP-A and PlGF will be useful to evaluate aspirin effects or guide the timing of aspirin discontinuation.